The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF)
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Date
2019-03-21Journal
Journal of Psychiatric ResearchPublisher
Elsevier Inc.Type
Article
Metadata
Show full item recordAbstract
There is considerable diversity in how treatment-resistant depression (TRD) is defined. However, every definition incorporates the concept that patients with TRD have not benefited sufficiently from one or more adequate trials of antidepressant treatment. This review examines the issues fundamental to the systematic evaluation of antidepressant treatment adequacy and resistance. These issues include the domains of interventions deemed effective in treatment of major depressive episodes (e.g., pharmacotherapy, brain stimulation, and psychotherapy), the subgroups of patients for whom distinct adequacy criteria are needed (e.g., bipolar vs. unipolar depression, psychotic vs. nonpsychotic depression), whether trials should be rated dichotomously as adequate or inadequate or on a potency continuum, whether combination and augmentation strategies require specific consideration, and the criteria used to evaluate the adequacy of treatment delivery (e.g., dose, duration), trial adherence, and clinical outcome. This review also presents the Antidepressant Treatment History Form: Short-Form (ATHF-SF), a completely revised version of an earlier instrument, and details how these fundamental issues were addressed in the ATHF-SF. © 2019 The AuthorsSponsors
LivaNova. Agency for Healthcare Research and Quality. Takeda Oncology. Foundation for Barnes-Jewish Hospital. Pfizer. Stanley Medical Research Institute. Forest Laboratories. ACADIA Pharmaceuticals. Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St. Louis. Johnson and Johnson. National Institute of Mental Health. Bristol-Myers SquibbRights/Terms
Attribution-NonCommercial-NoDerivs 3.0 United StatesKeyword
Antidepressant treatment resistanceBrain stimulation
Major depressive episode
Pharmacotherapy
Psychotherapy
Treatment-resistant depression
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063949695&origin=inward; http://hdl.handle.net/10713/8859ae974a485f413a2113503eed53cd6c53
10.1016/j.jpsychires.2019.03.021
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States